Geoffrey Beran Rose Sells 7,732 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 7,732 shares of Pulmonx stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $11,056.76. Following the completion of the sale, the insider directly owned 365,734 shares in the company, valued at approximately $522,999.62. This represents a 2.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Pulmonx Stock Up 11.8%

Shares of NASDAQ LUNG opened at $1.61 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The stock has a market capitalization of $66.41 million, a PE ratio of -1.21 and a beta of 0.07. Pulmonx Corporation has a one year low of $1.31 and a one year high of $8.12. The business’s fifty day moving average price is $1.76 and its 200-day moving average price is $1.78.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to analyst estimates of $21.73 million. Pulmonx had a negative net margin of 59.67% and a negative return on equity of 78.35%. On average, equities research analysts anticipate that Pulmonx Corporation will post -1.55 EPS for the current year.

Institutional Trading of Pulmonx

A number of hedge funds have recently bought and sold shares of LUNG. Bank of Montreal Can purchased a new position in shares of Pulmonx during the second quarter worth approximately $53,000. Corton Capital Inc. purchased a new stake in shares of Pulmonx in the 2nd quarter valued at $32,000. Los Angeles Capital Management LLC purchased a new position in Pulmonx in the 2nd quarter worth $84,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Pulmonx by 32.1% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock valued at $567,000 after buying an additional 53,148 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Pulmonx in the second quarter worth about $149,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx News Roundup

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Q4 beat — Pulmonx reported EPS of -$0.25 (vs. consensus -$0.39) and revenue of $22.6M (vs. ~ $21.7M), with narrower net loss and improved adjusted EBITDA, signaling operational improvement. Earnings Release / Call
• Positive Sentiment: Liquidity boost — Pulmonx closed a five‑year credit facility for up to $60M (initial $40M draw used to refinance debt, $20M undrawn subject to revenue milestones), extending debt maturities to 2031 and reducing near‑term refinancing risk. Credit Facility Release
• Positive Sentiment: Cost discipline and margins — Management executed a restructuring that cut operating expenses ~11% in Q4 and reported a Q4 gross margin of ~78%, supporting a clearer path toward profitability if sales reaccelerate. Earnings Call Highlights
• Neutral Sentiment: Analyst activity is mixed — D. Boral reaffirmed a Buy with a high $14 PT while Canaccord lowered its target to $5 but kept a Buy — divergent targets can attract trading interest but don’t change fundamentals. Analyst Notes
• Negative Sentiment: Guidance disappointment — 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), indicating a growth pause that limits near‑term upside until commercial momentum returns. Guidance / Results
• Negative Sentiment: Insider selling — multiple Form 4 filings show significant sales by the CEO, general counsel and other officers on March 2, which can amplify downside sentiment and supply pressure. SEC Form 4 (CEO) SEC Form 4 (Other)
• Negative Sentiment: Cost of capital and dilution risk — the new term loan carries a high spread (SOFR + 7% with a floor and PIK option) and includes warrants, improving liquidity but increasing interest expense and potential dilution. Loan / Warrants Coverage

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research report on Thursday. Canaccord Genuity Group cut their price target on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.38.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.